Biotech company Regeneron says that its COVID-19 antibody cocktail reduces the risk of infection by nearly 82 percent for eight months. 
On Monday, the company announced the results of its clinical trials, conducted in partnership with the National Institute of Allergy and Infectious Diseases, Fox News reports. 

“During the 8‑month assessment period, there were 0 hospitalizations for COVID-19 in the REGEN-COV group and 6 in the placebo group,” Regeneron said in a press release. “The fully human antibodies in REGEN-COV were developed to provide long-lasting protective effects without any artificial mutations or sequences.” 

“With infections still occurring despite widespread vaccination, the immunocompromised face an ongoing …